See-Mode Technologies, a MedTech startup based in Singapore and Australia that seeks to empower clinicians to better predict stroke, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its debut product, Augmented Vascular Analysis (AVA), a world-first medical Artificial Intelligence (AI) software for automated analysis and reporting of vascular ultrasound scans.
See-Mode Technologies, announced today it has raised a US$7 million Series A funding, led by Mass Mutual Ventures Southeast Asia (MMV SEA). Other participants in the round include existing investors Blackbird Ventures, Cocoon Capital, Entrepreneur First, and SGInnovate, besides a group of angels.
A former finalist in The Irish Times Innovation Awards, HealthBeacon has raised €12 million to date with backers including SGInnovate, a private company owned by the Singapore government. Other investors include Manatt Health, BVP, Elkstone Partners and Bill McCabe’s Oyster Capital.
NDR Medical Technology has raised S$8 million in a Series A funding round led by MicroPort Scientific, a Chinese medical device developer and manufacturer, NDR said on Monday. Other investors in the round include existing investor SGInnovate, and new investor Kava Ventures, a venture partnership founded by owners of medical tech distributor Transmedic.
“Prevention is better than cure” is the mantra spurring some of this year’s 30 Under 30 Asia listees in the Healthcare & Science category to start their health-tech ventures. Stroke is the world’s second-leading cause of death after heart disease, a statistic that inspired Milad Mohammadzadeh and Sadaf Monajemi in 2017 to launch See-Mode Technologies to better predict the risk of strokes.
Tech in Asia reported that Singapore-based healthtech startup Lucence has raised US$20 million in a series A round led by global healthcare provider IHH Healthcare, with participation from SGInnovate and Heliconia Capital, amongst others. Lucence, which is a spinoff from A*Star in 2016, uses liquid biopsy, a blood-based technology that’s less invasive than tissue biopsies, to help clinicians analyse a tumour and make treatment decisions. The new funds will enable the company to reach more patients across Asia and North America, and the company is planning to embark on new prospective clinical studies to evaluate its technology for early detection of multiple cancers.